Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Ventricular assist device Stories

2013-06-10 12:27:48

PLEASANTON, Calif., June 10, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in two upcoming investor conferences. On Thursday, June 13, the company will participate in the Goldman Sachs 34(th) Annual Global Healthcare Conference. Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company,...

2013-06-05 20:23:49

ST. LOUIS, June 5, 2013 /PRNewswire-USNewswire/ -- A research team led by Theodosios Alexander, Sc.D., Dean of Parks College Engineering, Aviation and Technology at Saint Louis University, was awarded $1.4 million (GBP886k) by the Invention for Innovation (i4i) Program of the National Institute for Health Research to develop a novel mechanical circulatory support device. The proposal is titled TURBOCARDIA: Mechanical Circulatory Support Installed via Minimally Invasive Surgery. Alexander...

2013-06-04 12:27:56

FRAMINGHAM, Mass. and SYDNEY, June 4, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Goldman Sachs 34th Annual Global Healthcare Conference at 8:00 a.m. PDT (11:00 am EDT) on Wednesday, June 12, 2013. The conference is being held June 11-13 at...

2013-05-30 08:24:36

35-Year-Old Father of Four Returns Home with New Donor Heart to New Baby Boy TUCSON, Ariz., May 30, 2013 /PRNewswire/ -- When Justin Ryder, 35, was discharged from University of Arizona Medical Center in Tucson on May 20, he had a new donor heart beating in his chest and a new baby boy waiting for him at home in Las Vegas, his heart transplant made possible by 83 days of life with the SynCardia temporary Total Artificial Heart. (Photo:...

2013-05-16 16:25:36

FRAMINGHAM, Mass. and SYDNEY, May 16, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 2013 UBS Global Healthcare Conference at 11:00 a.m. EDT on Monday, May 20, 2013. The conference is being held May 20-22, 2013 at the Sheraton New...

2013-05-16 08:29:20

Dr. Jack Copeland Recognized for His Landmark Contributions in the Field of Heart Transplantation TUCSON, Ariz., May 16, 2013 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that world-renowned heart surgeon and SynCardia co-founder Jack G. Copeland, MD, was awarded the prestigious Pioneer in Transplantation Award at the annual meeting of the...

2013-05-14 08:34:37

PLEASANTON, Calif., May 14, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Bank of America Merrill Lynch 2013 Health Care Conference on Thursday, May 16. Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company, beginning at 10:40 a.m., Pacific Daylight Time (1:40 p.m., Eastern...

2013-05-10 16:23:53

FRAMINGHAM, Mass. and SYDNEY, May 10, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2013 Health Care Conference at 8:00 a.m. PDT (11:00 am EDT) on Thursday, May 16, 2013. The conference is being held May...

2013-05-02 16:29:12

- Revenue of $117.7 million for the first quarter of 2013 PLEASANTON, Calif., May 2, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today reported its financial results for the first quarter of 2013. For the quarter ended March 30, 2013, Thoratec reported revenues of $117.7 million, a 7 percent decrease versus revenues of $126.8 million in the same...

2013-05-02 08:37:14

-- Phase II, randomized, placebo-controlled study at Glenfield Hospital, University of Leicester (UK) will measure primary efficacy endpoint of change from baseline in left ventricular ejection fraction (LVEF) post-percutaneous coronary intervention (PCI) -- TORONTO, May 2, 2013 /PRNewswire/ -- CellAegis Devices, Inc., announced today the first clinical trial program in the European Union to evaluate the use of the Company's autoRIC(TM) Device for Chronic Remote Ischemic Conditioning...


Latest Ventricular assist device Reference Libraries

0_886104d1c1c698f3a531e056704457d5
2010-10-14 16:46:25

The artificial heart, a mechanical heart replacement, is typically used in order to bridge the time to heart transplant or to replace the heart in case a transplant is impossible. Often ventricular assist devices are confused with mechanical hearts because the assist the heart through pumps. They are also different from a cardiopulmonary bypass machine which is an external device used to provide the function of the heart and lungs. CPBs are usually only used for a few hours at a time,...

More Articles (1 articles) »